Specialty Chemicals company Anupam Rasayan India announced Q1FY26 results Total revenue for Q1FY26 was at Rs 4,907 million as compared to Rs 2,603 million in Q1FY25; up 89% YoY. EBITDA (incl. other income) was at Rs 1,292 million in Q1FY26 as compared to Rs 592 million in Q1FY25, up 118% and this would translate into 26% EBITDA margin in this quarter. Profit After Tax was at Rs 485 million in Q1FY26 as compared to Rs 122 million in Q1FY25; up 297% YoY. Anand Desai, Managing Director, Anupam Rasayan, said: “During Q1FY26, consolidated revenue stood at Rs 491 crore, registering a robust growth of 89% year-on-year. We strongly believe that the sectoral trends are in our favour, and we are witnessing a clear resurgence in growth. Our pharma and polymer businesses are performing well, coupled with a recovery in the Agrochemical segment. The USA and Japan markets have shown encouraging trends for Anupam Rasayan. During Q1FY26, total exports accounted for 58% of the total revenue from operations. With the two new agreements signed with Japanese and US-based multinational companies, our order book now stands at Rs 14,646 crore, reflecting the strong growth momentum in our business.” Result PDF
Specialty Chemicals company Anupam Rasayan India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total revenue for Q4FY25 was at Rs 5,057 million as compared to Rs 4,130 million in Q4FY24; up 22% YoY. EBITDA (incl. other income) was at Rs 1,500 million in Q4FY25 as compared to Rs 1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter. Profit After Tax was at Rs 629 million in Q4FY25 as compared to Rs 405 million in Q4FY24; up 56% YoY. FY25 Financial Highlights: Total revenue for FY25 was at Rs 14,485 million as compared to Rs 15,053 million in FY24; down 4% YoY. EBITDA (incl. other income) was at Rs 4,123 million in FY25 as compared to Rs 4,109 million in FY24, this would translate into 28% EBITDA margin in FY25. Profit After Tax was at Rs 1,600 million in FY25 as compared to Rs 1,674 million in FY24. Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at Rs 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix. While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.” Result PDF
Conference Call with Anupam Rasayan India Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.